FIELD: medicine.
SUBSTANCE: invention relates to condensed bicyclic compounds, having affinity with mineralocorticoid receptor (VR) of formula [I] and formula [ii], as well as to pharmaceutical compositions on their basis. In general formula [I[ and [ii] ring A represents benzene ring, which has substituent R1, condensed with adjacent 6-membered heterocyclic ring, and said benzene ring additionally optionally is substituted with one or two substituent(s), selected from halogen atom and C1-8-alkyl group, R1 represents C1-8-alkylsulfonyl amino group or C1-8-alkyl aminosulfonyl group, R2 and R3 (a) are similar or different and represent group, selected from hydrogen atom, C1-8-alkyl group, and from 6- to 10-membered monocyclic or bicyclic aryl group (said aryl group is optionally substituted with halogen atom), (b) are combined with each other with formation of oxogroup or (c) are combined with each other on their ends together with adjacent carbon atom with formation of C3-10-cycloalkyl group, X represents the following group =N-, =C(R4)- or -CH(R4)-, R4 represents hydrogen atom, cyanogroup, halogen atom, C1-6-alkyl group, C2-6-alkenyl group, C3-10-dicloalkyl group, C1-7-alkanoyl group, carbamoyl group or C3-8cycloalkenyl group, Ar represents from 6- to 10-membered monocyclic or bicyclic aryl group, optionally containing one or several heteroatom(s), selected from sulphur atom, oxygen atom and nitrogen atom (said aryl group is optionally substituted with similar or different, one or two substituent(s), selected from halogen atom, cyanogroup, C1-8-alkyl group, trihalogen- C1-8-alkyl group and C1-8alkoxygroup), and dotted line represents presence or absence of double bond, Xa represents the following group =N- or =C(CN)-, RZ represents hydrogen atom or halogen atom, R25 and R35 represent alkyl group, and Ar3 represents phenyl group, optionally substituted with one or two group(s), which is(are) selected from halogen atom and trihalogenalkyl group.
EFFECT: compounds can be applied as antihypertensive medication.
15 cl, 18 tbl, 8 dwg, 71 ex
Title | Year | Author | Number |
---|---|---|---|
NITROGEN-CONTAINING HETEROBICYCLIC COMPOUNDS | 2007 |
|
RU2398769C2 |
TRICYCLIC COMPOUNDS OF BENZOPYRAN AS ANTIARRHYTHMIC AGENTS | 2005 |
|
RU2380370C2 |
USE OF EP4 RECEPTOR ANTAGONIST IN TREATMENT OF CARTILAGE DISEASE | 2014 |
|
RU2663620C2 |
BENZOPYRAN DERIVATIVE | 2005 |
|
RU2366658C2 |
USING EP4 RECEPTOR ANTAGONISTS IN TREATING IL-23-MEDIATED DISEASES | 2011 |
|
RU2571816C2 |
3-ALKYLIDENHYDRAZINO-HETEROARYL COMPOUNDS AS ACTIVATORS OF THROMBOPROTEIN RECEPTOR | 2004 |
|
RU2358970C2 |
NOVEL BICYCLIC HETEROCYCLIC COMPOUND | 2009 |
|
RU2518073C2 |
3-ETHYLIDENEHYDRAZINE-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS THROMBOPOIETIN RECEPTOR ACTIVATORS | 2005 |
|
RU2395505C2 |
HETEROCYCLIC COMPOUND | 2019 |
|
RU2815003C2 |
1,1,2,2-TETRA (HETERO) ARYLETHANES OR 1,1,2-TRI (HETERO) ARYL-2-HETEROCYCLYLETHANES AS POTASSIUM CHANNEL INHIBITORS | 2005 |
|
RU2344134C2 |
Authors
Dates
2012-11-27—Published
2008-07-31—Filed